Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

Abstract Background Two germ line Fc‐γ receptor (FCGR) polymorphisms, rs1801274 [FCGR2A; His(H)131Arg(R)] and rs396991 [FCGR3A; Phe(F)158Val(V)], produce altered proteins through amino acid substitutions. We previously reported that the FCGR2A H/H genotype was associated with longer overall survival...

Full description

Bibliographic Details
Main Authors: Daniel Shepshelovich, Amanda R. Townsend, Osvaldo Espin‐Garcia, Lidija Latifovic, Chris J. O’Callaghan, Derek J. Jonker, Dongsheng Tu, Eric Chen, Eric Morgen, Timothy J. Price, Jeremy Shapiro, Lillian L. Siu, Michiaki Kubo, Alexander Dobrovic, Mark J. Ratain, Wei Xu, Taisei Mushiroda, Geoffrey Liu
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Cancer Medicine
Subjects:
cetuximab
FCGR2A
FCGR3A
polymorphism
survival
Online Access:https://doi.org/10.1002/cam4.1819

Internet

https://doi.org/10.1002/cam4.1819

Similar Items